Cellerant Therapeutics, a San Carlos, Calif. developer of stem cell therapeutics for things like sickle cell disease treatment, has raised $4.4 million in a second round financing. It was reported by VentureWire (sub required), which cited a Securities and Exchange Commission filing.

Cellerant previously raised $25 million towards its Series B funding, having last added $9 million to the round in September 2005. Before that, the company also raised a $10 million funding in May 2003. Cellerant’s investors include Camelot Ventures, Eminent Venture Capital Group, Amgen Founder George Rathmann, Novel Bioventures, CX Venture Group, MPM Capital, Allen & Co. and BD Ventures.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member